// App-Quantinova.ai

5081 : Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC) An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.

Researchers

Presenter

  • Abhishek Tripathi

Principal Investigators

  • Yu-Hui Chen

  • David Frazier Jarrard

  • Noah M. Hahn

  • Jorge A. Garcia

  • Robert Dreicer

  • Glenn Liu

  • Maha H. A. Hussain

  • Daniel H. Shevrin

  • Matthew M. Cooney

  • Mario A. Eisenberger

  • Manish Kohli

  • Elizabeth R. Plimack

  • Nicholas J. Vogelzang

  • Joel Picus

  • Michael Anthony Carducci

  • Robert S. DiPaola

  • Christopher Sweeney

Medical Centers

  • Stephenson Cancer Center/The University of Oklahoma Health Sciences Center, Oklahoma City, OK.

  • Dana-Farber Cancer Institute, Boston, MA

  • University of Wisconsin Comprehensive Cancer Center, Madison, WI

  • Johns Hopkins Greenberg Bladder Center Institute, Johns Hopkins School of Medicine, Baltimore, MD

  • University Hospital Seidman Cancer Center, Cleveland, OH

  • University of Virginia Medical Center, Charlottesville, VA

  • Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

  • NorthShore University HealthSystem, Evanston, IL

  • University Hospitals Case Medical Center, Cleveland, OH

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

  • Fox Chase Cancer Center, Philadelphia, PA

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

  • Washington University School of Medicine, Division of Oncology, St. Louis, MO

  • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine,, Baltimore, MD

  • University of Kentucky, Lexington, KY

  • Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Urology

  • Oncology (ONC)

Disease

  • Prostate cancer

  • Bone metastases

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00309985

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved